CEA | Jotup

Edible Garden to Showcase Pulp Sustainable Line of Gourmet Sauces and Chili-Based Products Including Additional New Products at Natural Products EXPO WEST® 2024 in Anaheim, California, March 14th-16th

Retrieved on:

Thursday, March 7, 2024

CEA, EXPO, Whole Foods Market, Nature, Human, Food court, Condiment, National Organic Program, Edible, Dierbergs Markets, Target, Fast food

BELVIDERE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, announced that the Company will showcase its new line of Pulp sustainable gourmet sauces and chili-based products at the National Products EXPO WEST® 2024, booth #5274 in Anaheim, California from Thursday, March 14th to Saturday, March 16th.

Key Points:

National Products EXPO WEST® 2024 is produced by New Hope Network and co-located by Fresh Ideas Organic Marketplace.
The event annually attracts 60,000 to 65,000 participants with buyers constituting roughly 60% of the total.
The event will highlight the latest in natural and organic food and drink, eco-friendly beauty, and household items, as well as supplements and ingredients.
Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are excited to be back at EXPO WEST and showcase the Pulp line of sustainable gourmet sauces and chili-based products at EXPO WEST® 2024.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on:

Wednesday, March 6, 2024

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points:

Fourth Quarter 2023 and Recent Developments:
Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
Financial Results for the Fourth Quarter Ended December 31, 2023
For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.

Edible Garden Announces Appointment of Chanida Curnutt as Senior Vice President of Business Development and Compliance

Retrieved on:

Tuesday, March 5, 2024

Senior, CEA, Investment, Growth, Food, Business development, Commerce, Health, LLM, Georgetown University Law Center, LLB, Edible, Agriculture, Chulalongkorn University

BELVIDERE, NJ, March 05, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today announced that Chanida Curnutt has been appointed Senior Vice President of Business Development and Compliance.

Key Points:

BELVIDERE, NJ, March 05, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today announced that Chanida Curnutt has been appointed Senior Vice President of Business Development and Compliance.
Ms. Curnutt brings more than 13 years of experience in global business and transaction strategies, international trade and commerce, corporate governance, and regulatory compliance.
Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, “We are extremely pleased to welcome Chanida Curnutt to the Edible Garden team.
Furthermore, we believe that her comprehensive experience and insights into the Southeast Asian market will be invaluable as Edible Garden leverages international expansion opportunities.

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System

Retrieved on:

Tuesday, March 5, 2024

FACS, Hospital, MD, CEA, Professor, Physician, Vascular surgery, Stroke, Plaque, MBA, Risk, Cooper University Hospital, Silk, Patient, Anatomy, TCAR, Stenosis, SILK, Pharmaceutical industry

This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.

Key Points:

This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.
“New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions.
The ENROUTE Transcarotid Stent System features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization.
The stent system was purpose-built for TCAR with a short delivery system for ergonomic and precise stent delivery.

Norton Rose Fulbright welcomes two highly regarded financial services partners in New York

Retrieved on:

Monday, March 4, 2024

New York, March 04, 2024 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright today announced that financial services lawyers Steven Lofchie and Mark Highman have joined the firm as partners in the New York office.

Key Points:

New York, March 04, 2024 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright today announced that financial services lawyers Steven Lofchie and Mark Highman have joined the firm as partners in the New York office.
Regarded as one of the leading financial services practitioners in the US, Lofchie counsels clients on securities laws, the Commodity Exchange Act (CEA) and related bankruptcy issues in his regulatory practice.
Clients look to Norton Rose Fulbright to guide them through such challenges, and Steve and Mark further strengthen our multidisciplinary offering to the financial services industry.”
Vincent Dunn, Norton Rose Fulbright’s New York Co-Partner-in-Charge, commented:
“Norton Rose Fulbright’s New York office has been serving clients in the financial services sector for more than a century.
Norton Rose Fulbright provides a full scope of legal services to the world’s preeminent corporations and financial institutions.

Hydrofarm Holdings Group Announces Fourth Quarter and Full Year 2023 Results

Retrieved on:

Thursday, February 29, 2024

Hydroponics, CEA, Food, Adjustment, Line of credit, Capital expenditure, GAAP, Public expenditure, Insurance, Bookkeeping

SHOEMAKERSVILLE, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points:

Fourth Quarter 2023 Highlights vs.
Gross profit(2) increased to $37.6 million compared to $29.3 million; Gross Profit Margin(2) increased to 16.6% of net sales compared to 8.5%.
During 2023, the Company maintained a zero balance on its Revolving Credit Facility and was in compliance with debt covenants as of December 31, 2023.
The Company will host a conference call to discuss financial results for the fourth quarter 2023 today at 8:30 a.m. Eastern Time.

Edible Garden Announces New Grant Funding from Michigan Department of Labor and Economic Opportunity - Workforce Development Through West Michigan Works!

Retrieved on:

Thursday, February 22, 2024

Labour, CEA, Transport, Nature, Edible, Food safety

This funding is aimed at reimbursing employers in Western Michigan for costs incurred in the training, development, and retention of both existing and new employees.

Key Points:

This funding is aimed at reimbursing employers in Western Michigan for costs incurred in the training, development, and retention of both existing and new employees.
It supports the expansion and enhancement of employee skills, fosters opportunities for internal growth or promotion, and contributes to their economic progress.
Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are pleased to have been awarded this grant from the Michigan Department of Labor and Economic Opportunity – Workforce Development.
The grant will reimburse the Company for training expenses for our staff at the Edible Garden Heartland facility in Grand Rapids, Michigan, in crucial areas such as supply chain management, transportation, and logistics.

A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer

Retrieved on:

Monday, March 4, 2024

Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CEA, Food, Carcinoembryonic antigen, Safety, Patient, Orphan, Colorectal cancer, Pharmaceutical industry

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expression.

Key Points:

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expression.
A2B530 is the first autologous logic-gated cell therapy developed from A2 Bio’s proprietary TmodTM platform.
“The FDA granting Orphan Drug Designation validates the tremendous unmet need for improved therapies for patients with colorectal cancer,” said William Go, M.D., Ph.D, Chief Medical Officer of A2 Bio.
Orphan Drug Designation qualifies A2 Bio for certain development incentives related to the A2B530 clinical program, including tax credits for clinical trials, prescription drug user fee exemptions and potentially up to seven years of market exclusivity upon regulatory approval.

Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

Retrieved on:

Friday, March 8, 2024

TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid artery disease, a condition characterized by the narrowing or blockage of the carotid arteries in the neck.

Key Points:

TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid artery disease, a condition characterized by the narrowing or blockage of the carotid arteries in the neck.
Since its establishment in 2019, Genesis MedTech Group has continuously strived to enhance its peripheral interventional portfolio, offering comprehensive solutions to both physicians and patients.
Before the introduction of TCAR, moderate to severe carotid artery disease was generally treated clinically with two surgical methods: Carotid Endarterectomy (CEA) and Transfemoral Carotid Artery Stenting (TFCAS).
Together with Silk Road Medical, we remain dedicated to make better healthcare more accessible, improving patient care and outcomes."

Local Bounti Receives Patent for Stack & Flow Technology®

Retrieved on:

Wednesday, February 21, 2024

Plant, CEA, Patent, Economics, Environment

HAMILTON, Mont., Feb. 21, 2024 /PRNewswire/ -- Local Bounti Corporation (NYSE: LOCL) ("Local Bounti" or the "Company"), a breakthrough U.S. indoor agriculture company, announced today that the United States Patent and Trademark Office issued a patent to the Company on February 13, 2024 for its proprietary Stack & Flow Technology.

Key Points:

HAMILTON, Mont., Feb. 21, 2024 /PRNewswire/ -- Local Bounti Corporation (NYSE: LOCL) ("Local Bounti" or the "Company"), a breakthrough U.S. indoor agriculture company, announced today that the United States Patent and Trademark Office issued a patent to the Company on February 13, 2024 for its proprietary Stack & Flow Technology.
"It is exhilarating to think about all the families that will benefit from delicious, locally grown produce that we grow utilizing sustainable methods.
Local Bounti utilizes its proprietary Stack & Flow Technology at four of its six growing facilities to enhance productivity in support of its distribution to a national customer base that spans approximately 13,000 retail doors.
Stack & Flow Technology, which combines the best of vertical and greenhouse growing technologies, enables superior unit economics and efficiencies across the production cycle.